Abstract
Proton pump inhibitors (PPIs) are commonly used to treat acid-related diseases, most notably gastroesophageal reflux disease. PPIs are designed to shut down the gastric proton pump (H+/K+-ATPase) of parietal cells, thereby raising the pH of the stomach. While effective, a number of side effects have been associated with PPI use. Naturally occurring bacteria, some of which are acid-producing and contain ATPase enzymes, have also been found within the stomach, upper gastrointestinal tract, and oral cavity. Likewise, a number of fungi are known to inhabit the human body; some of these fungi contain H+-ATPase enzymes. Recent literature has suggested that PPIs may be inadvertently affecting these bacteria and fungi in two different ways: 1) PPIs may directly target the proton pumps of the bacteria and fungi, and/or 2) PPIs may indirectly affect the microenvironment of the flora via changes in pH. These unintended interactions are exasperated by the systemic distribution of PPIs throughout the body and may potentially lead to some of the side effects observed with PPI use. Herein we summarize what is currently known about the interactions between the PPIs and the natural human microbiota.
Keywords: Bacteria, C. difficile, fungi, gastroesophageal reflux disease (GERD), H. pylori, Lactobacilli, microbiota, proton pump inhibitors, (PPIs)
Current Drug Metabolism
Title: The Effect of Proton Pump Inhibitors on the Human Microbiota
Volume: 10 Issue: 1
Author(s): B. J. Vesper, A. Jawdi, K. W. Altman, G. K. Haines III, L. Tao and J. A. Radosevich
Affiliation:
Keywords: Bacteria, C. difficile, fungi, gastroesophageal reflux disease (GERD), H. pylori, Lactobacilli, microbiota, proton pump inhibitors, (PPIs)
Abstract: Proton pump inhibitors (PPIs) are commonly used to treat acid-related diseases, most notably gastroesophageal reflux disease. PPIs are designed to shut down the gastric proton pump (H+/K+-ATPase) of parietal cells, thereby raising the pH of the stomach. While effective, a number of side effects have been associated with PPI use. Naturally occurring bacteria, some of which are acid-producing and contain ATPase enzymes, have also been found within the stomach, upper gastrointestinal tract, and oral cavity. Likewise, a number of fungi are known to inhabit the human body; some of these fungi contain H+-ATPase enzymes. Recent literature has suggested that PPIs may be inadvertently affecting these bacteria and fungi in two different ways: 1) PPIs may directly target the proton pumps of the bacteria and fungi, and/or 2) PPIs may indirectly affect the microenvironment of the flora via changes in pH. These unintended interactions are exasperated by the systemic distribution of PPIs throughout the body and may potentially lead to some of the side effects observed with PPI use. Herein we summarize what is currently known about the interactions between the PPIs and the natural human microbiota.
Export Options
About this article
Cite this article as:
Vesper J. B., Jawdi A., Altman W. K., Haines III K. G., Tao L. and Radosevich A. J., The Effect of Proton Pump Inhibitors on the Human Microbiota, Current Drug Metabolism 2009; 10 (1) . https://dx.doi.org/10.2174/138920009787048392
DOI https://dx.doi.org/10.2174/138920009787048392 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Perspective of Natural Alkaloid Carbazole and its Derivatives as Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry TGF-Beta Signaling Manipulation as Potential Therapy for IBD
Current Drug Targets Aging and Inflammation: Etiological Culprits of Cancer
Current Aging Science Design, Synthesis and Pharmacological Evaluation of Gastro- Protective Anti-inflammatory Analgesic Agents based on Dual Oxidative Stress / Cyclooxygenase Inhibition
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Food-Derived Peptides and Intestinal Functions
Current Pharmaceutical Design miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke
MicroRNA Anticancer Actions of Omega-3 Fatty Acids - Current State and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Phytochemicals and Cancer Stem Cells: A Pancreatic Cancer Overview
Current Chemical Biology Alzheimer's Disease: Related Targets, Synthesis of Available Drugs, Bioactive Compounds Under Development and Promising Results Obtained from Multi-target Approaches
Current Drug Targets Clinical Application of Ghrelin
Current Pharmaceutical Design Hepatic Effects of Duloxetine-I: Non-Clinical and Clinical Trial Data
Current Drug Safety FOXM1 and its Oncogenic Signaling in Gastric Cancer
Recent Patents on Anti-Cancer Drug Discovery Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety Natural Naphthoquinones with Great Importance in Medicinal Chemistry
Current Organic Synthesis Novel 4- Aryl-2(1H)-phthalazinone Derivatives as Cyclooxygenase-2 Inhibitors: Synthesis, Molecular Modeling Study and Evaluation as Promising Anti-inflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Involvement of Cysteine Proteases in Cancer
Current Medicinal Chemistry Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Anti-Cancer Agents in Medicinal Chemistry Defensins: Key Molecules in Ocular Surface Protection
Current Immunology Reviews (Discontinued) Zinc-Permeable Ion Channels: Effects on Intracellular Zinc Dynamics and Potential Physiological/Pathophysiological Significance
Current Medicinal Chemistry Crosstalk of Long Non-coding RNAs and EMT: Searching the Missing Pieces of an Incomplete Puzzle for Lung Cancer Therapy
Current Cancer Drug Targets